[Cytosolic pS2 levels and cellular proliferation in ER-positive and PgR-positive infiltrating ductal carcinomas of the breast].
OBJECTIVE
The trefoil factor 1 (TFF1/pS2) is an estrogen-induced molecule in breast tumours. We wanted to study its expression in ER+ and PgR+ infiltrating ductal carcinomas of the breast (IDCs), and to correlate it with other clinical-biological parameters and the outcome.


METHODS
Cytosolic pS2 levels were measured using an IRMA (CIS. Biointernational. France) in 170 tumors. Likewise we determined the cytosolic levels of cathepsin D and tissue-type plasminogen activator (t-PA), as well as the concentrations of the epidermal growth factor receptor (EGFR), erbB2 oncoprotein, CD44v5 and CD44v6 on cell surfaces. Also the tumour size, histological grade (HG), axillary lymph node involvement, distant metastasis, ploidy, DNA index and of cellular synthesis phase (SP) was taken in account.


RESULTS
The pS2-positive (> 5 ng/mg prot.) tumours showed higher concentrations of cathepsin D (p: 0.0043) and t-PA (p: 0.0089) than the pS2-negative ones. Likewise, they were less frequently HG3 (p: 0.0231), SP > 7 % (p: 0.0005) and SP > 14% (p:0.0014). During the follow-up time (r: 1-147; 50,1+/-31,7; median 37 months) the pS2-positive tumors showed a less number of recurrences (5/101 vs 6/69; p: 0.059) but not of deaths by the tumor (1/101 vs 2/69).


CONCLUSIONS
These results support an inverse relationship between pS2 positivity and cellular proliferation in IDCs and suggest a new role of this protein (different of the hormone dependence) in the biology of these breast carcinomas, while further studies will be required to establish the impact of this finding on their outcome.
Sánchez Salmón
A
A
Servicio de Medicina Nuclear, Hospital Clínico Universitario, 15706 Santiago de Compostela.
Argibay
S
S
Arias
J I
JI
Ruibal
A
A
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000782:Aneuploidy; D001943:Breast Neoplasms / Q000737:chemistry* / Q000145:classification / Q000401:mortality / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000737:chemistry* / Q000401:mortality / Q000473:pathology; D002402:Cathepsin D / Q000032:analysis; D002455:Cell Division; D003600:Cytosol / Q000737:chemistry*; D004273:DNA, Neoplasm / Q000032:analysis; D018572:Disease-Free Survival; D066246:ErbB Receptors / Q000032:analysis; D004967:Estrogens; D005260:Female; D005500:Follow-Up Studies; D006023:Glycoproteins / Q000032:analysis; D006801:Humans; D018960:Hyaluronan Receptors / Q000032:analysis; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis* / Q000502:physiology; D009367:Neoplasm Staging; D009376:Neoplasms, Hormone-Dependent / Q000737:chemistry* / Q000401:mortality / Q000473:pathology; D011374:Progesterone; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D011960:Receptors, Estrogen / Q000032:analysis*; D011980:Receptors, Progesterone / Q000032:analysis*; D010959:Tissue Plasminogen Activator / Q000032:analysis; D000071163:Trefoil Factor-1; D025521:Tumor Suppressor Proteins / Q000032:analysis* / Q000502:physiology
D002402:Cathepsin D; D004273:DNA, Neoplasm; D066246:ErbB Receptors; D004967:Estrogens; D006023:Glycoproteins; D018960:Hyaluronan Receptors; D009363:Neoplasm Proteins; D011374:Progesterone; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D010959:Tissue Plasminogen Activator; D000071163:Trefoil Factor-1; D025521:Tumor Suppressor Proteins; C113800:CD44v5 antigen; C112697:CD44v6 antigen; C051838:TFF1 protein, human